Portfolio concentration
As of February 28, 2026 · N-PORT
Holdings
40
Top-10 weight
58.55%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
21
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
1124.7
Holdings
As of February 28, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | LILLY ELI and CO | — | 2,619 | $2.76M | 12.19% |
| 2 | JOHNSON&JOHNSON | — | 7,357 | $1.83M | 8.09% |
| 3 | ASTRAZENECA PLC | — | 6,923 | $1.45M | 6.40% |
| 4 | MERCK & CO | — | 10,915 | $1.35M | 5.98% |
| 5 | BOSTON SCIENTIFIC CORP | — | 17,062 | $1.31M | 5.80% |
| 6 | THERMO FISHER SCIENTIFIC INC | — | 2,001 | $1.04M | 4.61% |
| 7 | INTUITIVE SURGICAL INC | — | 2,003 | $1.01M | 4.46% |
| 8 | GUARDANT HEALTH INC | — | 8,978 | $843.03K | 3.73% |
| 9 | HOYA CORP | — | 4,523 | $818.85K | 3.62% |
| 10 | ARGENX SE SPONSORED ADR | — | 1,061 | $813.70K | 3.60% |
| 11 | CENCORA INC | — | 2,056 | $765.12K | 3.38% |
| 12 | ABBOTT LABS | — | 6,078 | $707.18K | 3.13% |
| 13 | LONZA GROUP -REG | — | 953 | $664.45K | 2.94% |
| 14 | AGILENT TECHNOLOGIES INC | — | 5,409 | $656.54K | 2.90% |
| 15 | DEXCOM INC | — | 8,247 | $605.58K | 2.68% |
| 16 | ROIVANT SCIENCES LTD | — | 17,375 | $502.83K | 2.22% |
| 17 | METTLER-TOLEDO INTL INC | — | 293 | $400.44K | 1.77% |
| 18 | APOGEE THERAPEUTICS INC | — | 5,225 | $365.75K | 1.62% |
| 19 | Sartorius Stedim Biotech S.A. | DIM | 1,658 | $358.44K | 1.59% |
| 20 | IONIS PHARMACEUTICALS INC | — | 3,918 | $317.95K | 1.41% |
| 21 | QIAGEN NV | — | 6,309 | $314.19K | 1.39% |
| 22 | REPLIGEN CORP | — | 2,204 | $283.72K | 1.26% |
| 23 | INSMED INC | — | 1,846 | $275.66K | 1.22% |
| 24 | PENUMBRA INC | — | 750 | $258.29K | 1.14% |
| 25 | Goldman Sachs Treasury Obligations Fund Institutional Class | FTOXX | 245,420 | $245.42K | 1.09% |
| 26 | NATERA INC | — | 1,137 | $236.54K | 1.05% |
| 27 | XENON PHARMACEUTICALS INC | — | 5,393 | $233.14K | 1.03% |
| 28 | ROYALTY PHARMA PLC | — | 4,939 | $228.23K | 1.01% |
| 29 | UNITEDHEALTH GRP | — | 775 | $227.28K | 1.01% |
| 30 | CYTOKINETICS INC | — | 3,546 | $220.63K | 0.98% |
| 31 | BRIDGEBIO PHARMA INC | — | 3,115 | $207.09K | 0.92% |
| 32 | MADRIGAL PHARMACEUTICALS INC | — | 466 | $201.31K | 0.89% |
| 33 | RHYTHM PHARMACEUTICALS INC | — | 2,150 | $199.37K | 0.88% |
| 34 | CG ONCOLOGY INC | — | 3,187 | $187.40K | 0.83% |
| 35 | ARCELLX INC | — | 1,623 | $184.68K | 0.82% |
| 36 | GENEDX HOLDINGS CORP-A | — | 1,664 | $132.64K | 0.59% |
| 37 | REVOLUTION MEDICINES INC | — | 1,159 | $118.24K | 0.52% |
| 38 | INSULET CORP | — | 432 | $106.54K | 0.47% |
| 39 | ULTRAGENYX PHARMA INC | — | 3,619 | $84.65K | 0.37% |
| 40 | STRUCTURE THERAPEUTICS INC ADR | — | 1,092 | $68.77K | 0.30% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.